Bioxcel Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Susan E. Atkins, a Director of BioXcel Therapeutics, Inc., received 17,000 shares of common stock on August 12, 2026.
NASDAQ
Chief Legal Officer Javier Rodriguez acquired 35 shares of BioXcel Therapeutics common stock through the vesting of restricted stock units.
NASDAQ
BioXcel Therapeutics CFO Richard Steinhart acquired 35 shares of common stock through the vesting of restricted stock units.
NASDAQ
Chief Scientific Officer Frank Yocca acquired 35 shares of BioXcel Therapeutics common stock through the vesting of restricted stock units.
NASDAQ
CEO Vimal Mehta acquired 219 shares of BioXcel Therapeutics common stock through the vesting of restricted stock units.
NASDAQ
Chief Scientific Officer Frank Yocca acquired 17,500 shares via RSU vesting and sold 6,845 shares to cover tax obligations.
NASDAQ
Chief Legal Officer Javier Rodriguez sold 6,560 shares of BioXcel Therapeutics to cover tax obligations following an RSU vest.
NASDAQ
BioXcel Therapeutics CFO Richard Steinhart reported the vesting of 17,500 RSUs and a subsequent sale of 6,845 shares to cover tax obligations.
NASDAQ
CEO Vimal Mehta acquired 49,758 shares via RSU vesting and sold 19,419 shares to cover tax obligations.
NASDAQ
BioXcel Therapeutics CEO Vimal Mehta acquired 18,000 shares of common stock through the vesting and exercise of restricted stock units.
NASDAQ
BioXcel Therapeutics CFO Richard Steinhart acquired 9,000 shares of common stock following the vesting of restricted stock units.
NASDAQ
Chief Scientific Officer Frank Yocca acquired 9,000 shares of BioXcel Therapeutics common stock through the vesting of restricted stock units.
NASDAQ
Chief Legal Officer Javier Rodriguez acquired 9,000 shares of BioXcel Therapeutics common stock following the vesting of restricted stock units.
NASDAQ
BioXcel Therapeutics CEO and President Vimal Mehta reported the acquisition of common stock through the conversion of Restricted Stock Units.
NASDAQ
BioXcel Therapeutics' Chief Financial Officer, Richard I. Steinhart, converted a total of 68 Restricted Stock Units into common stock on March 14 and 15, 2026.
NASDAQ
Javier Rodriguez, BioXcel Therapeutics' Chief Legal Officer, acquired 68 shares of common stock through the vesting of Restricted Stock Units.
NASDAQ
BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, exercised Restricted Stock Units, converting them into common stock and increasing his direct beneficial ownership.
NASDAQ
BioXcel Therapeutics director Sandeep Laumas was granted 17,000 stock options with an exercise price of $2.01, vesting based on service.
NASDAQ
BioXcel Therapeutics Director Rajiv Patni was granted 17,000 stock options with an exercise price of $2.01, vesting on the earlier of one year or the next annual meeting.
NASDAQ
BioXcel Therapeutics Director Peter Mueller received a grant of 17,000 stock options with an exercise price of $2.01, vesting over one year or by the next annual meeting.
NASDAQ
BioXcel Therapeutics Director Michal Votruba was granted 17,000 stock options with an exercise price of $2.01, vesting based on service.
NASDAQ
BioXcel Therapeutics, Inc. Director Michael Patrick Miller was granted 17,000 stock options with an exercise price of $2.01.
NASDAQ
BioXcel Therapeutics Director June Bray was granted 17,000 stock options with an exercise price of $2.01, vesting based on continued service.
NASDAQ
BioXcel Therapeutics Director David J. Mack was granted 17,000 stock options with an exercise price of $2.01, vesting based on service.
NASDAQ
Form 4: BioXcel CSO Granted 70,000 RSUs
BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, was granted 70,000 Restricted Stock Units with a two-year vesting schedule.
NASDAQ
BioXcel Therapeutics' Chief Financial Officer, Richard I. Steinhart, was granted 70,000 Restricted Stock Units, aligning his interests with long-term company performance.
NASDAQ
BioXcel Therapeutics' CEO and President, Vimal Mehta, was granted 199,032 Restricted Stock Units as part of an equity compensation plan.
NASDAQ
BioXcel Therapeutics, Inc. granted 70,000 Restricted Stock Units to Chief Legal Officer Javier Rodriguez, vesting over two years.
NASDAQ
BioXcel Therapeutics CEO and President Vimal Mehta reported the conversion of Restricted Stock Units into common stock on December 14 and 15, 2025.
NASDAQ
BioXcel Therapeutics' Chief Financial Officer, Richard I. Steinhart, converted Restricted Stock Units into common stock on December 14 and 15, 2025.